Vera Therapeutics, Inc. (VERA) Stock Price & How to Invest

Vera Therapeutics is a biotechnology company focused on autoimmune kidney disease. Its lead asset is atacicept (brand name TRUTAKNA, atacicept-vymj), a subcutaneous fusion protein that blocks two B-cell signaling proteins, BAFF and APRIL, which drive the antibody production behind IgA nephropathy (IgAN), a progressive disease that can lead to kidney failure. In the ORIGIN Phase 3 trial, atacicept cut proteinuria (protein leaking into urine, a key marker of kidney damage) by about 46% from baseline and roughly 42% versus placebo at 36 weeks, and on July 7, 2026 the FDA granted accelerated approval, making it the first dual BAFF/APRIL inhibitor cleared for IgAN.

The investment picture is a classic transition from a de-risked clinical story to an unproven commercial one. Vera carries no product revenue in its trailing results and posts large net losses typical of a late-stage biotech, but it holds a substantial cash cushion to fund a launch. The market capitalization near $3 billion reflects investor expectations for atacicept sales rather than current financials, so the debate is about how quickly Vera can win share in an IgAN market that already has five-plus approved drugs, and whether the kidney-function (eGFR) data expected in the second half of 2026 supports the planned filing for full approval.

Vera has no meaningful trailing product revenue and funds itself through large operating losses, so it depends on its cash balance and capital markets to reach sustained profitability. The IgAN market is already crowded, with atacicept arriving as roughly the sixth approved drug alongside offerings from Novartis, Travere, Otsuka and others, which pressures pricing and share. The accelerated approval is conditional on confirmatory eGFR data, and a weak or negative readout would threaten the label. As a largely single-product company, the stock is highly sensitive to launch execution, competitive dynamics, and safety signals, and its valuation already prices in significant commercial success.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Vera Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$0 (pre-commercial through Q1 2026)
• Net loss (Q1 2026): ~$121.0M
• Net loss per share (Q1 2026): ~$1.69
• Cash & marketable securities: ~$596.8M (as of Mar 31, 2026)
• Market cap: ~$3.1B
• Shares outstanding: ~71.8M

As of July 2026, Vera's valuation reflects expectations for atacicept sales rather than current financials, since the company reported no product revenue and a large net loss in the first quarter of 2026. Its roughly $597 million cash position gives it runway to fund the TRUTAKNA launch. Any earnings multiple is not meaningful until commercial revenue builds, so the stock trades on the addressable market and launch trajectory.

There are three common ways to get VERA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so VERA sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where VERA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

VERA is a freshly approved kidney-drug biotech where the science has been validated but the commercial ramp and full-approval readout are the story from here.

Whether VERA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VERA a buy?, and where the stock could go from here in the VERA stock forecast.

For income investors, whether VERA pays a dividend and how the payout looks is covered in does VERA pay a dividend?